Current medications approved in Europe and USA for the treatment of chronic hepatitis B (CHB) include interferon (IFN)-α, pegylated (PEG)-IFN-α2a, lamivudine (3TC), adefovir, entecavir, telbivudine and tenofovir disoproxil fumarate. 3TC, emtricitabine and tenofovir disoproxil fumarate are licensed for HIV type-1 (HIV-1) treatment and are active against both HIV-1 and hepatitis B virus (HBV). Therefore, important issues to be considered before starting anti-HBV therapy in HIV-1-coinfected patients include the risk of the development of HBV-and HIV-1-associated drug resistance and the indication for use of highly active antiretroviral therapy [1] [2] [3] . The rate of HBV resistance to 3TC in HIV-1-HBV-coinfected patients reached 90% at 4 years [4] , whereas no evidence of resistance mutations to adefovir were identified, neither for HBV nor HIV-1, at week 144 in HIV-1-HBVcoinfected patients with 3TC-resistant HBV when adefovir was added to the pre-existing antiretroviral therapy [5] .
Telbivudine is an HBV-specific l-nucleoside analogue of thymidine that specifically inhibits HBV polymerase [6, 7] . Telbivudine demonstrated no in vitro activity against HIV-1 in infected human peripheral blood mononuclear cells (PBMCs) [6, 8, 9] , thus it is currently recommended for the treatment of HBV infection in HIV-1-infected patients who do not meet criteria for antiretroviral therapy [2, 3, 10] . However, very few clinical data are available on this population at present.
We report here the first investigation of the administration of telbivudine as a monotherapy in three HIV-1-HBV-coinfected patients.
Patient 1
A 35-year-old HIV- During the follow-up, this patient never met the criteria for antiretroviral therapy (ART), with HIV-1 RNA levels ranging from 10 4 to 4×10 4 copies/ml and CD4 + T-cell counts >700 cells/µl. In May 2007, PEG-IFN-α2a therapy was started. After 9 months of therapy, HBV DNA had decreased from 10 8 to 6×10 5 copies/ ml; thus, PEG-IFN-α2a was stopped. Thereafter, telbivudine was initiated and HBV DNA decreased to an undetectable level (<308 copies/ml) at week 12, with concomitant normalization of aminotranferases. At 1 week following the introduction of telbivudine, plasma HIV-1 RNA decreased by 1 log 10 , from 2,500 to 211 copies/ml and, 1 week later, the HIV-1 viraemia was undetectable (<50 copies/ml). At week 4 of telbivudine therapy the HIV-1 RNA level returned to the pretreatment value (2,419 copies/ml) and maintained a positive replication until week 24 ( Figure 1A ). No changes in CD4 + T-cell count emerged during the observation period, as the values fluctuated between 976 and 650 cells/µl.
Patient 2
A 39-year-old HIV-1-infected Latin American homosexual man presented with an acute viral hepatitis B in January 2007, then developed an active chronic hepatitis with HBV DNA>10 8 copies/ml and alanine aminotransferase (ALT) ranging from 350 to 540 IU/l. HBeAg was persistently positive but the patient refused PEG-IFN-α2a therapy. HIV-1 infection did not meet the criteria for ART, HIV-1 RNA being steadily <40,000 copies/ml and CD4 + T-cell count >650 cells/µl. In March 2008 he began to receive telbivudine and HBV DNA dropped to 10 7 copies/ml at week 1 and to 4×10 3 at week 12, followed by ALT normalization. At week 24, HBV DNA was undetectable (<308 copies/ml). HIV-1 RNA level fluctuated between 8×10 3 and 2×10 4 copies/ml, without significant changes from pretreatment values ( Figure 1B ). CD4 + T-cell count remained between 654 and 620 cells/µl.
Patient 3
A 34-year-old Latin American homosexual man was hospitalized in April 2008 for acute hepatitis B. Liver 
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Telbivudine in HIV-1-HBV coinfection tests were aspartate aminotransferase 1,161 IU/l, ALT 2,744 IU/l and bilirubin 1.2 mg/dl; serological markers were consistent with acute HBV infection, with positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core immunoglobulin M antibodies, HBeAg and with HBV DNA 3×10 8 copies/ ml. He was also found to be HIV-1-infected, with a CD4 + T-cell count of 400 cells/µl and HIV-1 RNA of 6,599 copies/ml. At the end of June, because of the persistence of increased liver necrosis (ALT 2,393 IU/l), anti-HBV therapy with telbivudine was started. HBV DNA dropped to 10 7 copies/ml after 1 week and to an undetectable level (<308 copies/ml) at week 12. HIV-1 RNA level decreased to <50 copies/ml after 1 week on telbivudine and increased again during the follow-up to 4×10 3 copies/ml at week 24 ( Figure 1C ). CD4 + T-cell count was stable between 390 and 379 cells/µl over the study period.
Molecular analysis
RNA and DNA population-based sequence analysis of HIV-1 RT and protease regions was performed using commercial assays (Trugene TM; Siemens, NY, USA) and in-house methods, respectively [11] . The direct sequencing detects the majority of HIV-1 viral species with a sensitivity of 75-80%.
HBV DNA was extracted from 0.3 ml of plasma according to the manufacturer's instructions (Roche Diagnostic GmbH, Mannheim, Germany). Three partially overlapped HBV DNA fragments were amplified using homemade heminested-PCR protocols. HBV PCR amplicons were submitted to automated DNA sequencing (Applied Biosystems, Foster City, CA, USA) generating a sequence of 1,182 nucleotides comprising 85% of the large S gene and almost 50% of pol gene [12] .
Wild type HIV-1 (in both plasma and PBMCs) and HBV strains were carried by all patients at baseline and no mutations associated to drug resistance were found in both viruses at week 24. All patients harboured a B subtype of HIV-1.
Discussion
HIV-1-HBV-coinfected individuals who require only treatment of HBV should receive therapy with anti-HBV agents that are not active against HIV-1 to prevent the emergence of drug-resistant HIV-1 strains. Among available anti-HBV drugs, only PEG-IFN-α2a and adefovir have been assessed in HIV-1-HBV-coinfected patients naive for ART, although the latter has limited potency and some concerns persist about its potential ability to induce HIV-1 mutations [13] . Entecavir monotherapy is contraindicated as anti-HIV-1 activity associated with HIV-1 resistance mutations has been recently reported [14] . Therefore, the European AIDS Clinical Society guidelines for the treatment of CHB in HIV-1-infected patients recommend the use of PEG-IFN, telbivudine or telbivudine plus adefovir in patients with no indication for ART [2] .
Telbivudine has a higher anti-HBV potency compared with 3TC, showing a higher proportion of patients with undetectable HBV DNA at week 104, higher rate of HBeAg loss and lower rate of resistance [15] . Moreover, in a recent study, a greater antiviral effect of telbivudine than adefovir after 24 weeks of treatment in HBeAg positive patients was shown [16] . The main limitation of telbivudine is the low genetic barrier, as a single-site substitution (M204I) impairs the drug susceptibility, as confirmed by resistance rates of 25% and 10.8% in HBeAg-positive and HBeAg-negative patients, respectively, at 104 weeks of therapy. Nevertheless, the achievement of HBV DNA levels <3 log 10 copies/ml at week 24 of telbivudine therapy is predictive of more favourable 2-year outcomes [15] .
Despite the high HBV DNA levels at baseline, all three patients in our study showed HBV DNA levels <3 log 10 copies/ml after 24 weeks of telbivudine treatment and no resistance mutations emerged as detected by HBV DNA sequence. This result confirms the potent anti-HBV activity of telbivudine in HIV-1-HBV-coinfected patients. Notably, patient 3 was treated in a very early phase of infection, 3 months after the onset of acute hepatitis, and this could have favoured viral clearance regardless of telbivudine antiviral potency; nevertheless, the HBsAg and HBeAg persistence at week 24 of treatment is consistent with an unresolved acute HBV infection. Intriguingly, we observed a reduction of HIV-1 RNA between 2 and 3 log 10 copies/ml after the introduction of telbivudine in two out of three patients, followed by a rebound to baseline values. This observation, and the recent report on the unexpected anti-HIV-1 activity of entecavir [14] , prompted us to strictly monitor HIV-1 viraemia and the emergence of drug-related mutations either for HIV-1 or HBV. Sequence results showed wild-type viruses with no mutations in HIV-1 pol known to confer resistance to anti-HIV-1 drugs, both on viral RNA and proviral DNA. A clonal analysis of HIV-1 quasispecies was not undertaken because drug-related mutations were absent at all time points of HIV-1 RNA monitoring (baseline, and months 3, 4 and 6) despite the observed rebound.
The decrease of HIV-1 RNA might indirectly result from the inhibition of HBV replication, with a subsequent inhibitory effect on lymphocyte activation, cytokine release and liver inflammation. Preliminary data obtained in macrophages stimulated with mouse hepatitis virus type-3 show an increase of both messenger RNA and soluble type-1 cytokines (tumour necrosis factor-α, interleukin [IL]-12, IL-18 and IFN-γ) and a decrease of IL-4 because of a direct effect of telbivudine treatment, leading to an increased survival and an improved liver histology of susceptible CH3 mice [17] . Further studies are needed to investigate this hypothesis, given the rapid but transient reduction of HIV-1 RNA, despite the long-term inhibition of HBV replication.
A very recent case report of one HIV-1-HBVcoinfected patient treated with adefovir and telbivudine has been published [18] . The authors observed a transient reduction of HIV-1 RNA, either at telbivudine initiation or at its rechallenge, inferring that telbivudine has anti-HIV-1 activity. The concomitant use of adefovir with 3TC might have influenced the HIV-1 viral kinetics, as the drug-to-drug interaction of these molecules is unknown. In addition, the higher potency of the association against HBV or a direct immunomodulatory activity of telbivudine might explain the effect on HIV-1 replication, as previously discussed. Importantly, the absence of drug resistance mutations after HIV-1 viral rebound, as detected in the present study and also by Low et al. [18] failed to prove an anti-HIV-1 activity.
In conclusion, 24 weeks of telbivudine therapy showed a potent anti-HBV activity in HIV-1-positive HBeAg-positive patients with high HBV viraemia. Although a transient but deep reduction of HIV-1 RNA was observed in two of three patients, no genotypic mutations of drug resistance were found by specific molecular analysis of the target gene, suggesting an indirect mechanism of telbivudine activity on HIV-1 replication.
These data suggest a strict monitoring of HIV-1 viraemia in HIV-1-HBV-coinfected patients on telbivudine monotherapy. Further investigations on immune system activation markers are needed to better clarify the in vivo mechanisms of this drug.
